Literature DB >> 1606425

Multiple sclerosis: therapeutic pessimism.

H E Webb.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1606425      PMCID: PMC1881882          DOI: 10.1136/bmj.304.6837.1260

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  5 in total

1.  Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

Authors:  T A Yednock; C Cannon; L C Fritz; F Sanchez-Madrid; L Steinman; N Karin
Journal:  Nature       Date:  1992-03-05       Impact factor: 49.962

2.  Peripheral blood mononuclear cells from multiple sclerosis patients recognize myelin proteolipid protein and selected peptides.

Authors:  J L Trotter; W F Hickey; R C van der Veen; L Sulze
Journal:  J Neuroimmunol       Date:  1991-07       Impact factor: 3.478

3.  Evidence for subacute fat embolism as the cause of multiple sclerosis.

Authors:  P B James
Journal:  Lancet       Date:  1982-02-13       Impact factor: 79.321

4.  Oxygen immunosuppression: modification of experimental allergic encephalomyelitis in rodents.

Authors:  J Warren; M R Sacksteder; C A Thuning
Journal:  J Immunol       Date:  1978-07       Impact factor: 5.422

Review 5.  CSF antibodies to myelin basic protein and to myelin-associated glycoprotein in multiple sclerosis. Evidence of the intrathecal production of antibodies.

Authors:  A Wajgt; M Górny
Journal:  Acta Neurol Scand       Date:  1983-11       Impact factor: 3.209

  5 in total
  3 in total

1.  Minimising psychosocial disabilities of multiple sclerosis.

Authors:  A O Frank
Journal:  BMJ       Date:  1992-06-27

2.  Nonprescription medicine use in a multiple sclerosis clinic population.

Authors:  H L Tremlett; C M Wiles; D K Luscombe
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

Review 3.  Polyomavirus models of brain infection and the pathogenesis of multiple sclerosis.

Authors:  G L Stoner
Journal:  Brain Pathol       Date:  1993-07       Impact factor: 6.508

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.